Cantor Fitzgerald analyst Prahkar Agrawal initiated coverage of Oric Pharmaceuticals with an Overweight rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Oric Pharmaceuticals files to sell 12.5M shares of common stock for holders